Q-omics provides the consensus-scored FRAT2 profile across patient tissues and cancer cell-line models. FRAT2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FRAT2 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, FRAT2 RNA expression shows 18,632 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where FRAT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRAT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRAT2 survival associations across molecular data types. FRAT2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRAT2 RNA expression–survival associations across cancer types. High FRAT2 expression shows unfavorable associations in ACC and LIHC, but favorable associations in KIRC, SCLC, MESO and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify KIRC as the clearest survival context for FRAT2 RNA expression.
This table summarizes FRAT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FRAT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRAT2 shows lower tumor expression in THCA and higher tumor expression in LIHC, UCEC, LUSC, BLCA and STAD. The LIHC box plot shows higher FRAT2 RNA expression in tumor versus normal tissue (log2 FC = +1.026, t-test p < 0.001).
This table shows molecular features associated with FRAT2 in patient tissues and cancer cell lines. In patient samples, FRAT2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FRAT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
